Neuren Pharmaceuticals shares an update on the the company's Angelman Syndrome Clinical Study. July 8, 2023
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman
Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman, page-18
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.75 |
Change
-0.175(1.26%) |
Mkt cap ! $1.761B |
Open | High | Low | Value | Volume |
$13.94 | $13.96 | $13.50 | $3.260M | 238.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 310 | $13.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.75 | 366 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5 | 13.780 |
7 | 292 | 13.770 |
5 | 426 | 13.760 |
16 | 972 | 13.750 |
6 | 568 | 13.740 |
Price($) | Vol. | No. |
---|---|---|
13.790 | 1345 | 21 |
13.800 | 617 | 8 |
13.810 | 550 | 6 |
13.820 | 945 | 8 |
13.830 | 938 | 5 |
Last trade - 14.06pm 06/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |